公开(公告)号：EP3373935A1

公开(公告)日：2018-09-19

申请号：EP16864811.1

申请日：2016-11-07

申请人： Merck Sharp & Dohme Corp.

发明人： RUDD, Michael, T. ,  BRNARDIC, Edward, J. ,  KIM, Yuntae ,  MEISSNER, Robert, S. ,  RADA, Vanessa ,  STACHEL, Shawn, J. ,  ZERBINATTI, Celina, V.

IPC分类号： A61K31/496 ,  C07D401/04 ,  C07D241/04

CPC分类号： C07D295/16 ,  A61K31/496 ,  A61P3/10 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  C07D213/74 ,  C07D213/85 ,  C07D243/08 ,  C07D295/192 ,  C07D295/205 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D513/04 ,  C07D515/04

摘要： In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.